Sarcoma & GIST
Conference Coverage
Experimental LOXO-101 induces regression in several hard-to-treat cancers
Key clinical point:Inhibition of TRK gene fusion products is a novel strategy for treating cancer. Major finding: Three of three patients...
News
Adjuvant imatinib for 3 years better than 1 year in high-risk GIST
Key clinical point: Patients with high-risk GIST treated with adjuvant imatinib for 3 years had longer relapse-free survival (RFS) and overall...
News
Dose-intensive, multiagent regimen improves outcomes from low-risk rhabdomyosarcoma
Key clinical point: A dose-intensive, multiagent regimen including dose-compressed cycles of ifosfamide/etoposide and vincristine/doxorubicin/...
News
FDA approves trabectedin for some advanced soft tissue sarcomas
News
Trabectedin superior for advanced liposarcoma, leiomyosarcoma
Key clinical point: Trabectedin was superior to standard dacarbazine by most measures in advanced, refractory liposarcoma and leiomyosarcoma,...
News
Preop chemo feasible for high-risk soft-tissue sarcomas
Preoperative chemotherapy is feasible for high-risk localized soft-tissue sarcomas of the limbs or superficial trunk, even with concurrent...
Feature
Genomic oncology: moving beyond the tip of the iceberg
Conference Coverage
ASCO: Eribulin results ‘a giant step for sarcoma’
Key clinical point: Eribulin is the first drug shown in a clinical trial to offer a survival advantage over existing therapies for metastatic soft...